VRDN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
25.8M
+8967.6%
284.0K
+101.4%
141.0K
+6.8%
132.0K
-99.8%
70.6M
Cost of Revenue
1.5M
0
0
0
0
Gross Profit
24.2M
+8429.9%
284.0K
+101.4%
141.0K
+6.8%
132.0K
-99.8%
70.6M
Operating Expenses
127.7M
+0.9%
126.6M
+8.2%
117.0M
-4.8%
122.9M
+11.1%
110.6M
R&D
70.1M
-2.1%
71.6M
-7.8%
77.6M
-13.0%
89.2M
+3.4%
86.3M
SG&A
57.6M
+4.8%
55.0M
+42.1%
38.7M
+14.9%
33.7M
+38.4%
24.3M
Operating Income
-103477000
+18.0%
-126268000
-8.1%
-116841000
+4.8%
-122749000
-206.8%
-40013000
EBITDA
-103134000
+18.2%
-126151000
-8.1%
-116720000
+4.8%
-122629000
-207.3%
-39903000
Net Income
-101209000
+20.4%
-127119000
-21.2%
-104901000
+12.8%
-120355000
-247.9%
-34599000
EPS (Basic)
$-0.81
+22.9%
$-1.05
-16.7%
$-0.90
+15.9%
$-1.07
-214.7%
$-0.34
EPS (Diluted)
$-0.81
+22.9%
$-1.05
-16.7%
$-0.90
+15.9%
$-1.07
-214.7%
$-0.34
Shares (Diluted)
113.6M
+5.3%
107.9M
+5.5%
102.2M
+8.5%
94.2M
+14.8%
82.1M
Viridian Therapeutics (VRDN) — Financials